TRADING HALTED

My Portfolio
+
LINK YOUR PORTFOLIO

Bolt Biotherapeutics Inc 6LP0-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 06/06/25 CEST
5.18UNCH (UNCH)
52 week range
0.00 - 5.18
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close5.18
  • 52 Week High5.18
  • 52 Week High Date06/06/25
  • 52 Week Low0.00
  • 52 Week Low Date-

Latest On Bolt Biotherapeutics Inc

 

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-

Latest On Bolt Biotherapeutics Inc

 

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close5.18
  • 52 Week High5.18
  • 52 Week High Date06/06/25
  • 52 Week Low0.00
  • 52 Week Low Date-
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-

RATIOS/PROFITABILITY

  • EPS (TTM)-14.14
  • P/E (TTM)-0.37
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor...
William Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
Grant Yonehiro
Chief Operating Officer
Address
900 Chesapeake Drive
Redwood City, CA
94063
United States